Cytokine storm release syndrome and the prospects for immunotherapy with COVID-19, part 4: The role of JAK inhibition.

Journal

Cleveland Clinic journal of medicine
ISSN: 1939-2869
Titre abrégé: Cleve Clin J Med
Pays: United States
ID NLM: 8703441

Informations de publication

Date de publication:
01 Mar 2021
Historique:
pubmed: 28 8 2020
medline: 28 8 2020
entrez: 28 8 2020
Statut: aheadofprint

Résumé

This review focuses on an alternative strategy utilizing small molecules to inhibit a key signal-transduction pathway, the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway. The JAK-STAT pathway mediates biologic activity for a large number of inflammatory cytokines and mediators.

Identifiants

DOI: 10.3949/ccjm.87a.ccc060 PMID: 32847819
pubmed: 32847819
pii: ccjm.87a.ccc060
doi: 10.3949/ccjm.87a.ccc060
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2021 The Cleveland Clinic Foundation. All Rights Reserved.

Auteurs

Leonard H Calabrese (LH)

Department of Rheumatic and Immunologic Diseases, Orthopedic & Rheumatologic Institute, Cleveland Clinic calabrl@ccf.org.

Tiphaine Lenfant (T)

Department of Rheumatic and Immunologic Diseases, Orthopedic & Rheumatologic Institute Department of Infectious Disease, Cleveland Clinic.
Assistance Publique des Hôpitaux de Paris, Université de Paris.
Hôpital européen Georges Pompidou, Service de médecine interne, Paris, France.

Cassandra Calabrese (C)

Department of Rheumatic and Immunologic Diseases, Orthopedic & Rheumatologic Institute, and Department of Infectious Disease, Cleveland Clinic.

Classifications MeSH